SocialPicks Sentiment:
** v.s.
other stocks
|
This Quarter's Sentiment:
|
|
|
IMCL Analysis & Videos »
IMCL: Bull or Bear?
Discovery Labs: The Next Biotech Winner?
IMCL
|
|
|
+2.82%
in
424 days
<> I think the recent decline in Discovery Labs (DSCO) since the Company announced a minor delay in submitting a complete response to the FDA for an approvable ruling on Surfaxin represents a buying opportunity and bought some shares on Friday at $1.74 per share. Insider buying over the past two months (including a 75,000 share buy from the CEO at $1.87) demonstrates management's confidence in already meeting the FDA's requirements and the plan to submit a complete response to FDA for Surfaxin, which should now occur by about the third ...
|
ImClone Set to Sell at a Premium to Mystery Bidder
IMCL
|
|
|
+6.21%
in
7 days
(closed on 10/06/08)
ImClone Systems (IMCL) is set to sell itself for $6.1B or about $70 per share to the mystery big pharma bidder that Chairman Carl Icahn introduced as a defense against Bristol-Myers (BMY) original offer of $60, which was recently upped to $62 per share for the remaining 83% stake it does not already own. I have written about the saga on my blog since the end of July when Bristol-Myers made the original offer, but the Wall Street Journal s reporting the most likely bidders are Pfizer (PFE) or Eli Lilly (LLY).
Both of these big pharmas are in need of a pipeline and have the cash to...
|
Bristol-Myers Ups Bid to $62 for ImClone
IMCL
|
|
|
+1.09%
in
6 days
(closed on 09/29/08)
<> 
Last night, Bristol-Myers (BMY) announced plans to increase its bid for the remaining 83% of ImClone Systems (IMCL) it does not already own to $62 per share and plans to take the offer directly to shareholders in the form of a tender offer. ImClone and Chairman Carl Icahn rejected a $60 per share cash bid from Bristol-Myers at the end of July and stated that a mystery big pharma bidder had emerged at $70 per share, as I last wrote about here . Besides Bristol-Myers 17% stake in ImClone, the two companies are marketing pa...
|
ImClone Systems Inc.
IMCL
|
|
|
+80.26%
in
527 days
<> <> <> <> | Currency | US Dollars | | Share Price | $38.65 | | Change Today | $1.53 | | 52 Week High | $48.75 | | 52 Week Low | $30.36 | | Volume | 1,551,694 | | Beta | 0.65 | <> ...
|
Bearish on IMCL ...
IMCL
|
|
|
-54.93%
in
943 days
There isn't much novel here. Using antibodies to cure cancer may sound good but there could be adverse side effects from using antibodies. Also, their generally poor uptake requires a lot of material and many animals to produce these antibodies. Their margins look good but their PEG is 2.9 and P/E is 35. This doesn't look like a growth stock to me. On the plus size an 11% inside ownership shows the company isn't going to loose track of their finances.
|
People Bullish on IMCL
People Bearish on IMCL
|
ROCK-STAR INVESTORS
|
|
POPULAR STOCKS
|
|
TODAY'S HEADLINES
|
|
TODAY'S TOP PICKS
|
|
|
| StreetInsider.com on IMCL |
More Resources
|
About ImClone Systems Inc.
- Answers.com
